Novartis AG: EPS $2.46 vs $2.25 expected; revenue $14.52B vs $14.53B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 2.46 | 2.25 | +9.3% | 2.25 |
| Revenue (USD bn) | 14.52 | 14.53 | −0.1% | 14.36 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | Q3 FY2026 | 2.46 | 2.25 | +9.3% | 14.52 | 14.53 | −0.1% |
| Jul 21, 2026 | Q2 FY2026 | 2.41 | 2.17 | +11.1% | 14.41 | 14.07 | +2.4% |
| Apr 28, 2026 | Q1 FY2026 | 1.99 | 2.11 | −5.7% | 13.11 | 13.44 | −2.4% |
| Feb 4, 2026 | Q4 FY2025 | 2.03 | 1.99 | +2.0% | 13.34 | 13.70 | −2.7% |
| Oct 28, 2025 | Q3 FY2025 | 2.25 | 2.26 | −0.4% | 14.36 | 13.64 | +5.3% |
| Jul 17, 2025 | Q2 FY2025 | 2.42 | 2.38 | +1.7% | 14.28 | 13.94 | +2.5% |
| Apr 29, 2025 | Q1 FY2025 | 2.28 | 2.12 | +7.5% | 13.62 | 13.90 | −2.0% |
| Jan 31, 2025 | Q4 FY2024 | 1.98 | 1.80 | +10.0% | 13.56 | 12.84 | +5.6% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
Novartis AG results: EPS $2.46 vs $2.25 expected; revenue $14.52B vs $14.53B. The results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 9.3%; revenue below the estimate by 0.1%.
Revenue was up 1.1% from $14.36 billion a year earlier (Q3 FY2025). EPS was up 9.3% from $2.25 a year earlier. On its record, EPS topped analysts' estimates in 5 of 7 earlier comparable reports.
What the results mean
Revenue growth reflects an expanding business at Novartis AG, but interpreting the results requires examining the medicine mix and each therapeutic area's contribution. The nature of its operations makes sales composition important to understanding the relationship between business growth and profitability.
The company focuses on developing, manufacturing and marketing innovative medicines, particularly for oncology, immunology, neuroscience and cardiovascular diseases. Established medicine brands and specialized therapies complement this portfolio, making demand, product mix, and development and manufacturing costs central drivers of performance.
What to watch on the earnings call: Listen for management's discussion of demand across therapeutic areas and the contributions of innovative medicines and established brands to sales. Product mix, the effect of development and manufacturing costs on margins, and spending allocation across the therapeutic portfolio also merit attention.
For the full analysis of Novartis AG stock — valuation, scores and financial statements — see the stock page linked with this story.